Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMANTADINE HYDROCHLORIDE vs AMANTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amantadine hydrochloride is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of the M2 ion channel of influenza A virus, preventing viral uncoating and replication. In Parkinson's disease, it increases dopamine release and inhibits dopamine reuptake, and also acts as an NMDA glutamate receptor antagonist, reducing excitotoxicity.
Amantadine is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of viral uncoating, thereby blocking influenza A M2 ion channel. In Parkinson's disease, it is thought to increase dopamine release and inhibit its reuptake, and may also have anticholinergic and NMDA receptor antagonist effects.
Prophylaxis and treatment of influenza A virus infection,Treatment of Parkinson's disease and drug-induced extrapyramidal symptoms
Influenza A virus infection (prophylaxis and treatment),Parkinson's disease (symptomatic treatment),Drug-induced extrapyramidal reactions
For parkinsonism/drug-induced extrapyramidal symptoms: initial 100 mg twice daily; may increase to 300-400 mg/day in divided doses if needed. For influenza A treatment/prophylaxis in adults: 200 mg once daily or 100 mg twice daily; initiate prophylaxis as early as possible and continue for at least 10 days post-exposure.
100 mg orally twice daily for Parkinson's disease; 100 mg orally twice daily for influenza A prophylaxis/treatment (up to 200 mg/day).
Terminal elimination half-life: 10-14 hours in young adults; up to 34 hours in elderly (due to age-related decline in renal function); prolonged in renal impairment (up to 7 days in anuria).
Terminal elimination half-life: 10-14 hours in young adults, up to 24 hours in elderly; prolonged to >24 hours in renal impairment
Amantadine is primarily excreted unchanged in urine via glomerular filtration and tubular secretion. It undergoes minimal hepatic metabolism, with no major cytochrome P450 involvement.
Amantadine is primarily excreted unchanged in urine via glomerular filtration and tubular secretion. It undergoes minimal hepatic metabolism (less than 10%) with no major identified metabolites.
Renal: 90% unchanged drug via glomerular filtration and tubular secretion; minor fecal (<5%) and biliary elimination.
Renal: 90% as unchanged drug via glomerular filtration and tubular secretion; fecal: <10%
Approximately 67% bound to plasma proteins (mainly albumin).
60-70% bound, primarily to albumin
3-10 L/kg, indicating extensive tissue distribution (e.g., brain, lungs, erythrocytes).
Vd: 4-10 L/kg; indicates extensive tissue binding and penetration into brain (CSF: 50-80% of plasma concentration)
Oral bioavailability: 86-90% after immediate-release formulation; steady-state achieved within 4-7 days.
Oral: 86-90%; IV: 100%
Cr Cl 30-50 m L/min: 200 mg on day 1, then 100 mg once daily. Cr Cl 15-29 m L/min: 200 mg on day 1, then 100 mg every other day. Cr Cl <15 m L/min or on hemodialysis: 200 mg every 7 days. Adjust based on clinical response and tolerability.
Cr Cl 30-50 m L/min: 100 mg once daily; Cr Cl 15-29 m L/min: 100 mg every other day; Cr Cl <15 m L/min or hemodialysis: 200 mg every 7 days.
No specific dosage adjustment required in hepatic impairment, but use with caution due to potential central nervous system effects.
No specific Child-Pugh adjustments; use caution in severe hepatic impairment due to potential toxicity.
Influenza A treatment/prophylaxis: children 1-9 years: 4.4-8.8 mg/kg/day (max 150 mg/day) in 1-2 divided doses; 9-12 years: 100 mg twice daily; ≥12 years: adult dosing. Not routinely recommended due to widespread resistance.
Influenza A prophylaxis/treatment: 1-9 years: 5 mg/kg/day (max 150 mg/day) in 2 divided doses; 10-12 years: 100 mg twice daily; 13-16 years: 100 mg twice daily. Parkinson's: not recommended.
Initiate at 100 mg once daily or lower, considering age-related decline in renal function; titrate slowly with careful monitoring for adverse CNS effects.
Use lower starting dose (100 mg daily) due to age-related renal decline; frequent monitoring for neuropsychiatric effects.
None
None.
Risk of suicidality, especially in patients with a history of psychiatric disorders,May exacerbate seizure disorder; use with caution in epilepsy,Can cause orthostatic hypotension, dizziness, and blurred vision, impairing ability to drive or operate machinery,Neuroleptic malignant syndrome (NMS) has been reported with dose reduction or discontinuation,Renal function impairment requires dose adjustment; accumulation can cause toxicity,Elderly patients are more susceptible to CNS effects
Can cause CNS effects such as confusion, hallucinations, and seizures, especially in elderly or those with renal impairment,May exacerbate psychiatric disorders,Abrupt discontinuation may precipitate parkinsonian crisis or neuroleptic malignant syndrome in patients with Parkinson's disease,Avoid in patients with uncontrolled epilepsy,Renal dose adjustment required
Hypersensitivity to amantadine or any component of the formulation,Severe uncontrolled psychiatric disorder (relative)
Hypersensitivity to amantadine or any component,Severe uncontrolled epilepsy,Concomitant use with live attenuated influenza vaccine (since antiviral activity may impair vaccine efficacy)
Avoid alcohol and caffeine; alcohol may increase CNS depression, caffeine may exacerbate insomnia and nervousness. No specific food restrictions.
No specific food interactions. Avoid alcohol and limit caffeine intake due to potential increased CNS effects. Take with food if gastrointestinal upset occurs.
First trimester: Human data limited; animal studies (rat, rabbit) at doses 2-3 times human therapeutic dose showed increased fetal malformations (cardiovascular, skeletal). Second and third trimesters: No controlled data; case reports of preeclampsia, premature labor, and fetal distress with use near term. FDA Pregnancy Category C.
FDA Pregnancy Category C. First trimester: Associated with cardiovascular malformations (e.g., Ebstein anomaly) in retrospective studies; risk approximately 1-2% absolute. Second and third trimesters: Limited data; theoretical risk of fetal tachyarrhythmia and neurobehavioral effects. Human data insufficient to exclude risk.
Amantadine is excreted into breast milk; milk-to-plasma ratio (M/P) approximately 0.7-1.0 (based on single case, M/P 1.0 at 200 mg/day). Infant serum concentrations up to 6% of maternal therapeutic levels reported. Potential for anticholinergic effects and extrapyramidal symptoms in nursing infant. AAP recommends caution; weight benefits vs. risks.
Amantadine is excreted into breast milk with an M/P ratio of approximately 0.5. Limited human data; potential for adverse effects in nursing infants (e.g., irritability, urinary retention). Caution advised; use only if potential benefit outweighs risk.
Pregnancy increases renal clearance (by 20-50% in second/third trimester) due to increased glomerular filtration rate. For Parkinson's disease or influenza A, consider starting at lower dose (100 mg daily) and titrate upward as needed, monitoring for efficacy and CNS side effects. No standard dose adjustment guidelines; individualize based on therapeutic response and tolerance.
No specific pregnancy-related dosing adjustments established. Pharmacokinetic changes in pregnancy (increased renal clearance) may reduce serum levels; monitor clinical response and consider dose adjustment if efficacy wanes. Maximum dose 200 mg/day.
For Parkinson's disease, start at 100 mg twice daily; increase gradually to 100 mg TID or QID if needed. In elderly or renal impairment, reduce dose. Avoid abrupt discontinuation to prevent neuroleptic malignant syndrome. Monitor for orthostatic hypotension, livedo reticularis, and peripheral edema. Can worsen psychosis in patients with dementia. For influenza A, start within 48 hours of symptoms; not a substitute for vaccination. Use with caution in patients with seizure disorders or heart failure.
Amantadine is an antiviral and antiparkinsonian agent with NMDA receptor antagonist properties. For Parkinson's disease, it improves dyskinesias, especially levodopa-induced dyskinesias. For influenza A, it is less effective than neuraminidase inhibitors and resistance is common. Monitor for CNS effects (confusion, hallucinations, nightmares) especially in elderly or renally impaired patients. Dose adjustment required for Cr Cl <50 m L/min. Do not discontinue abruptly in Parkinson's disease due to risk of neuroleptic malignant syndrome.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,May cause dizziness or blurred vision; avoid driving until you know how this medicine affects you.,Avoid alcohol as it may increase side effects like dizziness.,Notify your doctor if you experience swelling in your legs or ankles, a lacy purple skin rash, or confusion.,If you miss a dose, take it as soon as you remember unless it is close to your next dose; do not double up.,Wear sunscreen and protective clothing; amantadine may make your skin more sensitive to sunlight.,Do not take this medicine for influenza unless directed by a doctor; it is not a substitute for the flu vaccine.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,Avoid alcohol as it may increase dizziness or confusion.,Report any unusual thoughts, hallucinations, or severe confusion to your healthcare provider immediately.,If you have Parkinson's disease, this medicine helps control symptoms but does not cure it.,If you are taking for influenza, finish the full course even if you feel better.,May cause blurred vision or dizziness; avoid driving or operating machinery until you know how it affects you.,Stay hydrated but avoid excessive caffeine as it may exacerbate side effects.
"Concurrent administration of naloxegol, a peripherally-acting mu-opioid receptor antagonist, may increase the serum concentration of amantadine, a weak NMDA receptor antagonist and antiviral agent. This interaction is proposed to occur via competitive inhibition of renal tubular secretion mediated by organic cation transporters (OCTs) present in the proximal tubule, leading to reduced amantadine clearance. Clinically, elevated amantadine levels can precipitate dose-related adverse effects including confusion, hallucinations, orthostatic hypotension, and peripheral edema, particularly in elderly patients or those with pre-existing renal impairment."
"Anagrelide is a phosphodiesterase 3 (PDE3) inhibitor with dose-dependent QT interval prolongation risk due to inhibition of the hERG potassium channel. Amantadine, a dopamine agonist and antiviral agent, also has mild QTc-prolonging properties, possibly through direct myocardial ion channel effects. Concomitant use may result in additive QT interval prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias."
"Amantadine, an antiviral and antiparkinsonian agent with weak NMDA receptor antagonist properties, may reduce the antipsychotic efficacy of mesoridazine, a phenothiazine antipsychotic. This interaction likely occurs via pharmacodynamic opposition, where amantadine's dopaminergic activity counteracts mesoridazine's dopamine receptor blockade in the central nervous system. Clinically, this can lead to worsening of psychotic symptoms or reduced therapeutic response to mesoridazine."
"Concurrent administration of naloxegol, a peripherally-acting mu-opioid receptor antagonist, may increase the serum concentration of amantadine, a weak NMDA receptor antagonist and antiviral agent. This interaction is proposed to occur via competitive inhibition of renal tubular secretion mediated by organic cation transporters (OCTs) present in the proximal tubule, leading to reduced amantadine clearance. Clinically, elevated amantadine levels can precipitate dose-related adverse effects including confusion, hallucinations, orthostatic hypotension, and peripheral edema, particularly in elderly patients or those with pre-existing renal impairment."
"Anagrelide is a phosphodiesterase 3 (PDE3) inhibitor with dose-dependent QT interval prolongation risk due to inhibition of the hERG potassium channel. Amantadine, a dopamine agonist and antiviral agent, also has mild QTc-prolonging properties, possibly through direct myocardial ion channel effects. Concomitant use may result in additive QT interval prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias."
"Amantadine, an antiviral and antiparkinsonian agent with weak NMDA receptor antagonist properties, may reduce the antipsychotic efficacy of mesoridazine, a phenothiazine antipsychotic. This interaction likely occurs via pharmacodynamic opposition, where amantadine's dopaminergic activity counteracts mesoridazine's dopamine receptor blockade in the central nervous system. Clinically, this can lead to worsening of psychotic symptoms or reduced therapeutic response to mesoridazine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMANTADINE HYDROCHLORIDE vs AMANTADINE, answered by our medical review team.
AMANTADINE HYDROCHLORIDE is a Antiviral / Antiparkinsonian that works by Amantadine hydrochloride is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of the M2 ion channel of influenza A virus, preventing viral uncoating and replication. In Parkinson's disease, it increases dopamine release and inhibits dopamine reuptake, and also acts as an NMDA glutamate receptor antagonist, reducing excitotoxicity.. AMANTADINE is a Antiviral / Antiparkinsonian that works by Amantadine is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of viral uncoating, thereby blocking influenza A M2 ion channel. In Parkinson's disease, it is thought to increase dopamine release and inhibit its reuptake, and may also have anticholinergic and NMDA receptor antagonist effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMANTADINE HYDROCHLORIDE and AMANTADINE depend on the specific clinical indication. These are both Antiviral / Antiparkinsonian agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMANTADINE HYDROCHLORIDE is: For parkinsonism/drug-induced extrapyramidal symptoms: initial 100 mg twice daily; may increase to 300-400 mg/day in divided doses if needed. For influenza A treatment/prophylaxis in adults: 200 mg once daily or 100 mg twice daily; initiate prophylaxis as early as possible and continue for at least 10 days post-exposure.. The standard adult dose of AMANTADINE is: 100 mg orally twice daily for Parkinson's disease; 100 mg orally twice daily for influenza A prophylaxis/treatment (up to 200 mg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining AMANTADINE HYDROCHLORIDE and AMANTADINE. Amantadine, an antiviral and antiparkinsonian agent with weak NMDA receptor antagonist properties, may reduce the antipsychotic efficacy of mesoridazine, a phenothiazine antipsychotic. This interaction likely occurs via pharmacodynamic opposition, where amantadine's dopaminergic activity counteracts mesoridazine's dopamine receptor blockade in the central nervous system. Clinically, this can lead to worsening of psychotic symptoms or reduced therapeutic response to mesoridazine. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. AMANTADINE HYDROCHLORIDE is classified as Category C. First trimester: Human data limited; animal studies (rat, rabbit) at doses 2-3 times human therapeutic dose showed increased fetal malformations (cardiovascular, skeletal). Second . AMANTADINE is classified as Category C. FDA Pregnancy Category C. First trimester: Associated with cardiovascular malformations (e.g., Ebstein anomaly) in retrospective studies; risk approximately 1-2% absolute. Second a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.